MicroRNA as therapeutic targets for treatment of depression

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1011-1021

  Hansen, Katelin F ^a   Obrietan, Karl ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

BDNF; Depression; Dicer; Microrna; miRNA; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; MICRORNA; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CIRCADIAN RHYTHM; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RNA ANALYSIS; RNA SYNTHESIS; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; STRESS; TRANSCRIPTION REGULATION;

EID: 84880958214     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S34811     Document Type: Review

References (142)

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196.
2. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003;12(1):3-21.
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.
4. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010; 1803(11):1231-1243.
5. Hunsberger JG, Austin DR, Chen G, Manji HK. MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromolecular Med. 2009;11(3):173-182.
6. O'Connor RM, Dinan TG, Cryan JF. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol Psychiatry. 2012;17(4):359-376.
7. Dwivedi Y. Evidence demonstrating role of microRNAs in the etiopathology of major depression. J Chem Neuroanat. 2011;42(2):142-156.
8. Mouillet-Richard S, Baudry A, Launay JM, Kellermann O. MicroRNAs and depression. Neurobiol Dis. 2012;46(2):272-278.
9. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69 Suppl E1:4-7.
10. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-389.
11. Tian JW, Jiang WL, Zhong Y, et al. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. Neuroscience. 2011;196:124-130.
12. Hercher C, Turecki G, Mechawar N. Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J Psychiatr Res. 2009;43(11):947-961.
13. Kempton MJ, Salvador Z, Munafò MR, et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry. 2011;68(7):675-690.
14. Arnone D, McIntosh AM, Ebmeier KP, Munafò MR, Anderson IM. Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. Eur Neuropsychopharmacol. 2012;22(1):1-16.
15. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516-1518.
16. Hajszan T, MacLusky NJ, Leranth C. Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. Eur J Neurosci. 2005;21(5): 1299-1303.
17. Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience. 1999;91(4):1247-1255.
18. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20(24):9104-9110.
19. Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000;5(3): 262-269.
20. Horan WP, Pogge DL, Borgaro SR, Stokes JM, Harvey PD. Learning and memory in adolescent psychiatric inpatients with major depression: a normative study of the California Verbal Learning Test. Arch Clin Neuropsychol. 1997;12(6):575-584.
21. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1558-1568.
22. Li N, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69(8):754-761.
23. Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry. 2002;7 Suppl 1:S29-S34.
24. Pezawas L, Meyer-Lindenberg A, Goldman AL, et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry. 2008;13(7):709-716.
25. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64(6):527-532.
26. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50(4):260-265.
27. Qi X, Lin W, Wang D, Pan Y, Wang W, Sun M. A role for the extracellular signal-regulated kinase signal pathway in depressive-like behavior. Behav Brain Res. 2009;199(2):203-209.
28. Todorovic C, Sherrin T, Pitts M, Hippel C, Rayner M, Spiess J. Suppression of the MEK/ERK signaling pathway reverses depressionlike behaviors of CRF2-deficient mice. Neuropsychopharmacology. 2009;34(6):1416-1426.
29. Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol. 2009;12(10):1337-1354.
30. Gourley SL, Wu FJ, Kiraly DD, et al. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry. 2008;63(4):353-359.
31. Dwivedi Y, Rizavi HS, Conley RR, Pandey GN. ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Mol Psychiatry. 2006;11(1): 86-98.
32. Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, Pandey GN. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem. 2001;77(3):916-928.
33. Dwivedi Y, Rizavi HS, Teppen T, et al. Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects. Neuropsychopharmacology. 2008;33(10):2324-2340.
34. Shelton RC, Sanders-Bush E, Manier DH, Lewis DA. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience. 2009;158(4):1406-1415.
35. Shelton RC, Hal Manier D, Lewis DA. Protein kinases A and C in postmortem prefrontal cortex from persons with major depression and normal controls. Int J Neuropsychopharmacol. 2009;12(9):1223-1232.
36. Pandey GN, Dwivedi Y, Pandey SC, Conley RR, Roberts RC, Tamminga CA. Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci Lett. 1997;228(2):111-114.
37. Dwivedi Y, Rao JS, Rizavi HS, et al. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60(3):273-282.
38. Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry. 2001;49(9): 753-762.
39. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull. 2001;55(5):585-595.
40. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6(3):219-233.
41. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry. 2012;83(5):495-502.
42. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.
43. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171-186.
44. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457.
45. Pace TW, Miller AH,Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci. 2009;1179: 86-105.
46. Syvälahti E, Eskola J, Ruuskanen O, Laine T. Nonsuppression of cortisol in depression and immune function. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(4):413-422.
47. Meltzer HY, Lowy MT, Koenig JI. The hypothalamic-pituitaryadrenal axis in depression. Adv Biochem Psychopharmacol. 1987;43: 165-182.
48. Monteleone P, Martiadis V, Maj M. Circadian rhythms and treatment implications in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1569-1574.
49. Mendlewicz J. Disruption of the circadian timing systems: molecular mechanisms in mood disorders. CNS Drugs. 2009;23 Suppl 2:15-26.
50. Kupfer DJ, Foster FG, Reich L, Thompson SK, Weiss B. EEG sleep changes as predictors in depression. Am J Psychiatry. 1976;133(6): 622-626.
51. Kupfer DJ. REM latency: a psychobiologic marker for primary depressive disease. Biol Psychiatry. 1976;11(2):159-174.
52. Kafi-De St Hilaire S, Merica H, Gaillard JM. The effects of indalpine - a selective inhibitor of 5-HT uptake - on rat paradoxical sleep. Eur J Pharmacol. 1984;98(3-4):413-418.
53. Nicholson AN, Pascoe PA. 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. Neuropharmacology. 1986;25(10):1079-1083.
54. Bliss EL. Sleep in schizophrenia and depression: studies of sleep loss in man and animals. Res Publ Assoc Res Nerv Ment Dis. 1967;45: 195-210.
55. Vogel GW, Vogel F, McAbee RS, Thurmond AJ. Improvement of depression by REM sleep deprivation. New findings and a theory. Arch Gen Psychiatry. 1980;37(3):247-253.
56. Georgotas A, McCue RE, Cooper TB, Nagachandran N, Friedhoff A. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res. 1989;28(1):1-9.
57. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854.
58. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735-739.
59. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75(5):855-862.
60. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
61. Kozomara A, Griffiths-Jones S,miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011;39(Database issue):D152-D157.
62. Kim J, Krichevsky A, Grad Y, et al. Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci U S A. 2004;101(1):360-365.
63. Kosik KS. The neuronal microRNA system. Nat Rev Neurosci. 2006;7(12):911-920.
64. Giraldez AJ, Cinalli RM, Glasner ME, et al. MicroRNAs regulate brain morphogenesis in zebrafish. Science. 2005;308(5723):833-838.
65. Cuellar TL, Davis TH, Nelson PT, et al. Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc Natl Acad Sci U S A. 2008;105(14): 5614-5619.
66. Davis TH, Cuellar TL, Koch SM, et al. Conditional loss of Dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus. J Neurosci. 2008;28(17):4322-4330.
67. Cheng HY, Papp JW, Varlamova O, et al. microRNA modulation of circadian-clock period and entrainment. Neuron. 2007;54(5): 813-829.
68. Hansen KF, Karelina K, Sakamoto K, Wayman GA, Impey S, Obrietan K. miRNA-132: a dynamic regulator of cognitive capacity. Brain Struct Funct. 2013;218(3):817-831.
69. Hollander JA, Im HI, Amelio AL,et al. Striatal microRNA controls cocaine intake through CREB signalling. Nature. 2010;466(7303):197-202.
70. Beveridge NJ, Cairns MJ. MicroRNA dysregulation in schizophrenia. Neurobiol Dis. 2012;46(2):263-271.
71. Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008;14(1):27-41.
72. Ghahramani Seno MM, Hu P, Gwadry FG, et al. Gene and miRNA expression profiles in autism spectrum disorders. Brain Res. 2011;1380: 85-97.
73. Hansen KF, Sakamoto K, Obrietan K. MicroRNAs: a potential interface between the circadian clock and human health. Genome Med. 2011;3(2):10.
74. Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol Psychiatry. 2011;69(2):188-193.
75. Xu Y, Liu H, Li F, et al. A polymorphism in the microRNA-30e precursor associated with major depressive disorder risk and P300 waveform. J Affect Disord. 2010;127(1-3):332-336.
76. Perkins DO, Jeffries CD, Jarskog LF, et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol. 2007;8(2):R27.
77. Schepeler T, Holm A, Halvey P, et al. Attenuation of the betacatenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene. 2012;31(22):2750-2760.
78. Zhou R, Yuan P, Wang Y, et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology. 2009;34(6):1395-1405.
79. Eacker SM, Keuss MJ, Berezikov E, Dawson VL, Dawson TM. Neuronal activity regulates hippocampal miRNA expression. PLoS One. 2011;6(10):e25068.
80. Kim AH, Reimers M, Maher B, et al. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res. 2010;124(1-3):183-191.
81. Rong H, Liu TB, Yang KJ, et al. MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res. 2011;45(1): 92-95.
82. Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol. 2013;23(7):602-611.
83. Oved K, Morag A, Pasmanik-Chor M, et al. Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics. 2012;13(10):1129-1139.
84. Millan MJ. MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. Curr Opin Pharmacol. 2011;11(1):11-22.
85. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science. 2010;329(5998): 1537-1541.
86. Launay JM, Mouillet-Richard S, Baudry A, Pietri M, Kellermann O. Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16. Transl Psychiatry. 2011;1:e56.
87. Jensen KP, Covault J, Conner TS, Tennen H, Kranzler HR, Furneaux HM. A common polymorphism in serotonin receptor 1B mRNA moderates regulation by miR-96 and associates with aggressive human behaviors. Mol Psychiatry. 2009;14(4):381-389.
88. Guo AY, Sun J, Jia P, Zhao Z. A novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC Syst Biol. 2010;4:10.
89. Numakawa T, Richards M, Adachi N, Kishi S, Kunugi H, Hashido K. MicroRNA function and neurotrophin BDNF. Neurochem Int. 2011;59(5):551-558.
90. Mellios N, Huang HS, Grigorenko A, Rogaev E, Akbarian S. A set of differentially expressed miRNAs, including miR-30a-5p, act as posttranscriptional inhibitors of BDNF in prefrontal cortex. Hum Mol Genet. 2008;17(19):3030-3042.
91. Angelucci F, Croce N, Spalletta G, et al. Paroxetine rapidly modulates the expression of brain-derived neurotrophic factor mRNA and protein in a human glioblastoma-astrocytoma cell line. Pharmacology. 2011;87(1-2):5-10.
92. Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet. 1998;352(9142):1754-1755.
93. Thome J, Sakai N, Shin K, et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci. 2000;20(11):4030-4036.
94. Böer U, Alejel T, Beimesche S, et al. CRE/CREB-driven up-regulation of gene expression by chronic social stress in CRE-luciferase transgenic mice: reversal by antidepressant treatment. PLoS One. 2007;2(5):e431.
95. Smalheiser NR, Lugli G, Rizavi HS, et al. MicroRNA expression in rat brain exposed to repeated inescapable shock: differential alterations in learned helplessness vs non-learned helplessness. Int J Neuropsychopharmacol. 2011;14(10):1315-1325.
96. Rajasethupathy P, Fiumara F, Sheridan R, et al. Characterization of small RNAs in Aplysia reveals a role for miR-124 in constraining synaptic plasticity through CREB. Neuron. 2009;63(6):803-817.
97. Klein ME, Lioy DT, Ma L, Impey S, Mandel G, Goodman RH. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci. 2007;10(12):1513-1514.
98. Cheng A, Wang S, Cai J, Rao MS, Mattson MP. Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain. Dev Biol. 2003;258(2):319-333.
99. Obrietan K, Gao XB, Van Den Pol AN. Excitatory actions of GABA increase BDNF expression via a MAPK-CREB-dependent mechanism: a positive feedback circuit in developing neurons. J Neurophysiol. 2002;88(2):1005-1015.
100. Remenyi J, Hunter CJ, Cole C, et al. Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins. Biochem J. 2010;428(2):281-291.
101. Vo N, Klein ME, Varlamova O, et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci U S A. 2005;102(45):16426-16431.
102. Impey S, Davare M, Lesiak A, et al. An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling. Mol Cell Neurosci. 2010;43(1):146-156.
103. Wayman GA, Davare M, Ando H, et al. An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc Natl Acad Sci U S A. 2008;105(26):9093-9098.
104. Alvarez-Saavedra M, Antoun G, Yanagiya A, et al. miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum Mol Genet. 2011;20(4):731-751.
105. Kadener S, Menet JS, Sugino K, et al. A role for microRNAs in the Drosophila circadian clock. Genes Dev. 2009;23(18):2179-2191.
106. Xu S, Witmer PD, Lumayag S, Kovacs B, Valle D. MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organspecific miRNA cluster. J Biol Chem. 2007;282(34):25053-25066.
107. Nagel R, Clijsters L, Agami R. The miRNA-192/194 cluster regulates the Period gene family and the circadian clock. FEBS J. 2009;276(19):5447-5455.
108. Saus E, Soria V, Escaramís G, et al. Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. Hum Mol Genet. 2010;19(20): 4017-4025.
109. Claes S. Glucocorticoid receptor polymorphisms in major depression. Ann N Y Acad Sci. 2009;1179:216-228.
110. Calabrese F, Molteni R, Racagni G, Riva MA. Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology. 2009;34 Suppl 1:S208-S216.
111. Meerson A, Cacheaux L, Goosens KA, Sapolsky RM, Soreq H, Kaufer D. Changes in brain MicroRNAs contribute to cholinergic stress reactions. J Mol Neurosci. 2010;40(1-2):47-55.
112. Rinaldi A, Vincenti S, De Vito F, et al. Stress induces region specific alterations in microRNAs expression in mice. Behav Brain Res. 2010;208(1):265-269.
113. Uchida S, Nishida A, Hara K, et al. Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor. Eur J Neurosci. 2008;27(9):2250-2261.
114. Uchida S, Hara K, Kobayashi A, et al. Early life stress enhances behavioral vulnerability to stress through the activation of REST4mediated gene transcription in the medial prefrontal cortex of rodents. J Neurosci. 2010;30(45):15007-15018.
115. Zimmerman G, Soreq H. Readthrough acetylcholinesterase: a multifaceted inducer of stress reactions. J Mol Neurosci. 2006;30(1-2): 197-200.
116. Meshorer E, Bryk B, Toiber D, et al. SC35 promotes sustainable stress-induced alternative splicing of neuronal acetylcholinesterase mRNA. Mol Psychiatry. 2005;10(11):985-997.
117. Shaltiel G, Hanan M, Wolf Y, et al. Hippocampal microRNA 132 mediates stress-inducible cognitive deficits through its acetylcholinesterase target. Brain Struct Funct. 2013;218(1):59-72.
118. Madrigal JL, García-Bueno B, Caso JR, Pérez-Nievas BG, Leza JC. Stress-induced oxidative changes in brain. CNS Neurol Disord Drug Targets. 2006;5(5):561-568.
119. Vreugdenhil E, Verissimo CS, Mariman R, et al. MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology. 2009;150(5):2220-2228.
120. Turner JD, Alt SR, Cao L, et al. Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more. Biochem Pharmacol. 2010;80(12):1860-1868.
121. Kawashima H, Numakawa T, Kumamaru E, et al. Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression. Neuroscience. 2010;165(4):1301-1311.
122. O'Connor RM, O'Leary OF, Dinan A, Gokul A, Dinan TG, Cryan JF. Stress-induced alterations in hippocampal and amygdalar microRNAs: effects of lithium. European Neuropsychopharmacology. 2010;20(August):S166-S167.
123. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198-201.
124. Mattes J, Collison A, Plank M, Phipps S, Foster PS. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci U S A. 2009;106(44):18704-18709.
125. Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 2008;105(10):3903-3908.
126. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9): 721-726.
127. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478(7369):404-407.
128. Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474(7353):649-653.
129. He Y, Zhou Y, Xi Q, et al. Genetic variations in microRNA processing genes are associated with susceptibility in depression. DNA Cell Biol. 2012;31(9):1499-1506.
130. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173-178.
131. Hoyer D, Thakker DR, Natt F, et al. Global down-regulation of gene expression in the brain using RNA interference, with emphasis on monoamine transporters and GPCRs: implications for target characterization in psychiatric and neurological disorders. J Recept Signal Transduct Res. 2006;26(5-6):527-547.
132. Thakker DR, Natt F, Hüsken D, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci U S A. 2004;101(49):17270-17275.
133. Thakker DR, Natt F, Hüsken D, et al. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry. 2005;10(8):782-789, 714.
134. Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, van Oudenaarden A. MicroRNAs can generate thresholds in target gene expression. Nat Genet. 2011;43(9):854-859.
135. Chtarto A, Bockstael O, Tshibangu T, Dewitte O, Levivier M, Tenenbaum L. A next step in adeno-associated virus (AAV)-mediated gene therapy for neurological diseases: regulation and targeting. Br J Clin Pharmacol. Epub January 18, 2013.
136. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013;20(4):450-459
137. Samaranch L, Salegio EA, San Sebastian W, et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther. 2012;23(4):382-389.
138. Belzeaux R, Bergon A, Jeanjean V, et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry. 2012;2:e185.
139. Mo MH, Chen L, Fu Y, Wang W, Fu SW. Cell-free circulating miRNA biomarkers in cancer. J Cancer. 2012;3:432-448.
140. Karolina DS, Tavintharan S, Armugam A, et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab. 2012;97(12):E2271-E2276.
141. Zhao C, Dong J, Jiang T, et al. Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One. 2011;6(8):e23925.
142. Leuenberger N, Jan N, Pradervand S, Robinson N, Saugy M. Circulating microRNAs as long-term biomarkers for the detection of erythropoiesis-stimulating agent abuse. Drug Test Anal. 2011;3(11-12):771-776.